Myostatin

Silencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

Maintaining skeletal muscle mass is crucial for health, as muscle atrophy caused by drugs, cancer, or aging poses serious risks. However, there are few effective pharmacological interventions targeting muscle atrophy, highlighting the need for new therapeutic strategies. In this study,...

๐Ÿ—“๏ธ 2025-10-03
๐Ÿ“ฐ Publication: Advanced Healthcare Materials
Read MoreSilencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

Sarcopenia, a progressive decline in skeletal muscle mass and function, has emerged as a critical geriatric syndrome affecting 10-40% of older adults, contributing to increased disability and mortality. This comprehensive review evaluates evidence-based strategies for sarcopenia management, from established interventions...

๐Ÿ—“๏ธ 2025-06-11
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreTherapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

Adipokines and Myokines as Markers of Malnutrition and Sarcopenia in Patients Receiving Kidney Replacement Therapy: An Observational, Cross-Sectional Study.

Chronic kidney disease (CKD) is linked to an elevated risk of malnutrition and sarcopenia, contributing to the intricate network of CKD-related metabolic disorders. Adipokines and myokines are markers and effectors of sarcopenia and nutritional status. The aim of this study...

๐Ÿ—“๏ธ 2024-07-31
Read MoreAdipokines and Myokines as Markers of Malnutrition and Sarcopenia in Patients Receiving Kidney Replacement Therapy: An Observational, Cross-Sectional Study.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!